SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) is a Healthcare company (Biotechnology) with a market capitalization of $4.2B. The Maz Rating grades it against the other companies in its sector.
SELLAS Life Sciences Group, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $20.71, SELLAS Life Sciences Group, Inc. trades at 11.5x book value. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -31.9%, return on invested capital of -29.8% and a free cash flow yield of -1.8%. On the balance sheet: a debt-to-equity ratio of 0.00 and a current ratio of 14.92. Over the past 52 weeks the share price ranged from $1.39 to $24.89, with a beta of 2.70.
SELLAS Life Sciences Group, Inc. does not currently pay a dividend.
5 Wall Street analyst ratings cover the stock: 5 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, SELLAS Life Sciences Group, Inc. (SLS) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 6.05% / 30% · Interest income / Revenue 121800000.0% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 6.05% / 33% · Receivables / Mkt Cap (36m) 0.00% / 49% · Interest income / Revenue 121800000.0% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 6.05% / 33.33% · Receivables / Mkt Cap (24m) 0.00% / 33.33% · Interest income / Revenue 121800000.0% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 0.54% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 94.4% / 33.33% · Receivables / Avg Assets (4Q) 0.00% / 33.33% · Interest income / Revenue 121800000.0% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 95.5% / 33.33% · (Cash+Recv) / Total Assets 95.5% / 33.33% · Interest income / Revenue 121800000.0% / 5% | Fail |
No. As of September 2026, SELLAS Life Sciences Group, Inc. (SLS) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. SELLAS Life Sciences Group, Inc. is over the AAOIFI limit on Interest income / Revenue.
About 121800000.0% of each dividend: SELLAS Life Sciences Group, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.